文献速递炎症性肠病消化道肿瘤与早癌

I-CARE:评估生物制剂治疗炎症性肠病安全性与有效性的欧洲前瞻性队列研究

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-09-22

I-CARE是一项欧洲前瞻性纵向观察性多中心队列研究,纳入至少3个月前确诊的克罗恩病、溃疡性结肠炎或未分类炎症性肠病患者,主要评估抗肿瘤坏死因子及其他生物制剂单药或联合免疫调节剂治疗下癌症/淋巴瘤和严重感染的风险。2016年3月至2019年4月共纳入10206例患者,其中克罗恩病6169例(60.4%)、溃疡性结肠炎3853例(37.8%)、未分类炎症性肠病184例(1.8%)。

要点

  • I-CARE为欧洲前瞻性纵向观察性多中心队列研究,计划长期评估生物制剂在炎症性肠病中的获益与风险。
  • 2016年3月至2019年4月共纳入10206例患者,克罗恩病6169例(60.4%),溃疡性结肠炎3853例(37.8%)。
  • 入组时47.3%使用抗肿瘤坏死因子药物,8.8%使用维得利珠单抗,3.4%使用乌司奴单抗。

核心结论

  • I-CARE是一项正在进行的、由研究者发起的欧洲前瞻性观察性队列研究,将为炎症性肠病患者生物治疗的长期获益与风险提供独特信息。

研究设计与样本

  • I-CARE设计为欧洲前瞻性纵向观察性多中心队列研究,纳入至少3个月前确诊的克罗恩病、溃疡性结肠炎或未分类炎症性肠病患者。
  • 2016年3月至2019年4月共纳入10206例患者,其中克罗恩病6169例(60.4%)、溃疡性结肠炎3853例(37.8%)、未分类炎症性肠病184例(1.8%)。

主要发现

  • 研究入组时,32%的患者使用硫唑嘌呤/硫嘌呤类药物,4.6%使用6-巯基嘌呤,3.2%使用甲氨蝶呤。
  • 入组时47.3%的患者接受抗肿瘤坏死因子药物治疗,8.8%接受维得利珠单抗治疗,3.4%接受乌司奴单抗治疗。
  • 约四分之一(26.8%)的患者既往接受过炎症性肠病相关手术,66%的患者既往接受过全身性糖皮质激素治疗。
  • 3%的患者入组前有癌症病史,1.1%有结肠、食管或子宫颈高级别异型增生病史。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with anti-tumor necrosis factor and other biologic monotherapy as well as in combination with immunomodulators. METHODS: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study to include patients with a diagnosis of Crohn's disease, ulcerative colitis, or IBD unclassified established at least 3 months prior to enrollment. RESULTS: A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6169 (60.4%) patients with Crohn's disease, 3853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving azathioprine/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one-quarter of patients (26.8%) underwent prior IBD-related surgery. Sixty-six percent of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion and 1.1% had a history of colonic, esophageal, or uterine cervix high-grade dysplasia. CONCLUSIONS: I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients. (EudraCT, Number: 2014-004728-23; ClinicalTrials.gov, Number: NCT02377258).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Peyrin-Biroulet L, Rahier JF, Kirchgesner J, et al. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 36152897. doi:10.1016/j.cgh.2022.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。